Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
Dexcom, Inc. reported strong first quarter 2026 results with faster growth and higher profitability. Revenue rose 15% year-over-year to $1.1919 billion, driven by 11% U.S. growth and 26% international growth. GAAP gross margin improved to 62.9% and non-GAAP gross margin reached 63.5%.
GAAP operating income increased to $255.3 million, or 21.4% of revenue, while non-GAAP operating income was $264.4 million, or 22.2% of revenue, reflecting sizable margin expansion versus 2025. GAAP net income nearly doubled to $199.5 million, or $0.51 per diluted share, and non-GAAP diluted EPS rose to $0.56.
Dexcom ended March 31, 2026 with $2.42 billion in cash, cash equivalents and marketable securities and no borrowings on its revolving credit facility. The company highlighted progress with its G7 15 Day CGM U.S. launch and Stelo platform, and raised 2026 guidance for non-GAAP operating and Adjusted EBITDA margins while reiterating revenue and non-GAAP gross margin targets.
Dexcom Inc Schedule 13G filer Vanguard Capital Management reports beneficial ownership of 28,848,218 shares of Common Stock, representing 7.49% of the class as of 03/31/2026. The filing states sole dispositive power over 28,848,218 shares and sole voting power over 3,827,257 shares.
The filing notes ownership includes securities held by Vanguard funds and certain affiliates exercising dispositive or voting power per SEC Release No. 34-39538. The reporting person is Vanguard Capital Management; transactions or changes after the reported date are not included in this excerpt.
Dexcom Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 19,322,566 shares of Common Stock, representing 5.02% of the class as of 03/31/2026. The filing shows sole dispositive power over 19,322,566 shares and sole voting power of 102,613 shares. The disclosure states ownership includes securities held by Vanguard funds and certain affiliates and is signed on 04/29/2026 by Ashley Grim.
Dexcom Inc.’s EVP and Chief Legal Officer Michael Jon Brown sold 1,700 shares of common stock in an open-market transaction. The shares were sold at $63.04 each under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025.
Following this sale, Brown directly owns 111,204 Dexcom shares77,603 unvested RSUs, with grants made on March 8, 2026, March 8, 2025, and March 8, 2024 that are scheduled to vest through March 8, 2029.
DexCom, Inc. is asking stockholders to elect twelve directors, ratify Deloitte & Touche LLP as auditor for 2026, and approve 2025 executive pay on an advisory basis. The company highlights strong 2025 performance, including $4.66 billion in revenue (up 16% from 2024) and $836.3 million in net income (up 45%).
Operating income reached $911.8 million and operating cash flow was $1.44 billion, ending 2025 with $2.00 billion in cash, cash equivalents and short-term marketable securities. Dexcom also repurchased $500.0 million of stock under a $750.0 million authorization and expanded its customer base to about 3.5 million global users.
The proxy details a refreshed, mostly independent Board, including new directors with medical, pharmaceutical and technology backgrounds, a lead independent director structure, comprehensive committee oversight (audit, compensation, nominating and governance, and technology), an insider trading and clawback policy, and a pay program emphasizing equity-based compensation and stock ownership guidelines for directors and executives.
Michael Brown submitted a Form 144 notice indicating an intended sale of 1,700 shares of Common Stock originally acquired as restricted stock. The filing shows transaction dates of 03/08/2026 (acquisition) and 03/16/2026 (sale activity), with the filing recorded on 04/15/2026.
Dexcom Inc ownership filing: The Vanguard Group filed an amendment stating it beneficially owns 0 shares of Dexcom common stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, where certain Vanguard subsidiaries will report disaggregated beneficial ownership.
Dexcom Inc. executive Michael Jon Brown, EVP and Chief Legal Officer, reported an open-market sale of 1,700 shares of common stock at $64.85 per share. The transaction occurred on March 16, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025.
After this sale, Brown directly holds 112,904 Dexcom shares. This figure includes 77,603 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029, reflecting a substantial continuing equity stake aligned with the company’s long-term performance.